SCHEMBL6797210

SCHEMBL6797210

CCOC(=O)c1cc(F)c(N2CCN(C)CC2)nc1NC1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NR2F2 P24468 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPK1 P28482 1/20 0.44
NPC1 O15118 1/20 0.43
S1PR2 O95136 1/20 0.43
LMNA P02545 1/20 0.43
XBP1 P17861 1/20 0.43
RAB9A P51151 1/20 0.43
PPP1CA P62136 1/20 0.43
OPRK1 P41145 4/20 0.43
TRPV4 Q9HBA0 1/20 0.42
SIK1 P57059 1/20 0.41
SIK2 Q9H0K1 1/20 0.41
SIK3 Q9Y2K2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796678 0.92 NR2F2 (0.48) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL6802757 0.85 SYK (0.44) SIK1SIK2SIK3RETROS1
SCHEMBL10466984 0.81 KDM4E (0.48) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL6795770 0.80 MEN1 (0.53) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL6797514 0.77 TRPA1 (0.45) NPC1RAB9ASIK1SIK2SIK3
SCHEMBL4506732 0.77 L3MBTL1 (0.46) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL10468168 0.77 NR2F2 (0.52) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL6794889 0.74 CHRM3 (0.46) ROCK2ROCK1
SCHEMBL10466972 0.72 ROCK2 (0.46) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL4503743 0.71 ALOX15 (0.50) MAPTRAB9AROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP disclosed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A KMT2A 3798/4885MEN1 2437/4885KDM4E 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.